In a continuation of their collaboration to increase clinical trial participation among patients from underrepresented racial and ethnic groups, the American Society of Clinical Oncology (ASCO) and Association of Community Cancer Centers (ACCC) today announced plans to test a research site assessment tool and implicit bias training program, both of which are designed to address one of the barriers to clinical trial participation: trials not routinely being offered by clinicians to eligible patients.
Advances in the treatment of prostate, breast, lung, and renal cancers as well as screening, prevention, access to care, immunotherapy, and precision medicine will be highlighted in the 2021 American Society of Clinical Oncology (ASCO) Annual Meeting’s official Press Program. Studies featured in the Press Program are among the more than 4,900 abstracts part of the Meeting.
Researchers, patient advocates, and global oncology leaders who have worked to reshape cancer care around the world are among the recipients of the American Society of Clinical Oncology’s (ASCO) Special Awards—the Society’s highest honors—and the Women Who Conquer Cancer Mentorship Awards from Conquer Cancer, the ASCO Foundation.
The Association for Clinical Oncology (ASCO) presented its Advocate of the Year Award to Jasmine Kamboj, MD, for her exceptional contributions to advocacy efforts to improve cancer care and research. A current member of ASCO’s Health Equity Committee, Dr. Kamboj volunteered much of her time to advocate on behalf of cancer advocacy priorities that impact people with cancer and their cancer care teams.
The Association for Clinical Oncology (ASCO) presented Senators Richard Burr (R-NC) and Ben Cardin (D-MD) with the annual Congressional Champion for Cancer Care Award in recognition of their ongoing commitment to legislation that improves the environment for cancer research, oncology practice, and the quality of care for patients. The award honors Members of Congress who are leading champions for patients and survivors of cancer, their families, and their cancer care teams.
The Association for Clinical Oncology (ASCO) applauds the proposed $9 billion funding increase for the National Institutes of Health (NIH) in President Biden’s budget request for Fiscal Year (FY) 2022. Such a significant proposed investment in biomedical research demonstrates a real commitment from the Administration to supporting the nation’s research infrastructure.
As part of its ongoing efforts to increase the diversity of the oncology workforce, the American Society of Clinical Oncology (ASCO) is launching a new internship program for medical students from populations underrepresented in medicine (UIM)1, and today announced five medical schools across the country that have been selected to serve as hosts in the inaugural Oncology Summer Internship (OSI) program. The selected medical schools include: The Ohio State University; the University of Arizona Health Sciences College of Medicine – Tucson; the University of California San Francisco (UCSF); the University of Pittsburgh; and the University of Rochester.
The Association for Clinical Oncology (ASCO) congratulates Xavier Becerra on his confirmation as Secretary of the Department of Health and Human Services (HHS). Secretary Becerra is now in a key position to lead HHS during the agency’s continued response to the COVID-19 pandemic and to address the many challenges facing patients and providers across the cancer care delivery system, such as health care disparities and the high cost of care.
The Association of Clinical Oncology congratulates the eleven practices that prioritized the quality of care they provide by achieving the Quality Oncology Practice Initiative (QOPI®) Certification in the second half of 2020.
In the midst of growing concerns that patients with cancer have limited access to the COVID-19 vaccines, the Association for Clinical Oncology (ASCO) and American Cancer Society Cancer Action Network (ACS CAN), advocacy affiliate of the American Cancer Society, today issued a joint letter to every state governor in the United States urging them to prioritize patients with cancer in the distribution of COVID-19 vaccines in accordance with U.S. Centers for Disease Control and Prevention (CDC) guidelines.
The American Society of Clinical Oncology (ASCO) and Friends of Cancer Research (Friends) jointly issued new recommendations to further efforts to broaden eligibility criteria in cancer clinical trials with the goal of making clinical trials more accessible to patients. The joint recommendations are detailed in a series of articles published in Clinical Cancer Research, a journal of the American Association for Cancer Research. The series provides a comprehensive examination of eligibility criteria for cancer clinical trials with recommendations to address five specific areas: treatment washout periods, concomitant medications, prior therapies, laboratory reference ranges and test intervals, and patient performance status.
Reduced levels of screening for prostate cancer using prostate-specific antigen (PSA) testing correspond with recent increases in the diagnosis of metastatic disease, according to a study that will be presented at the 2021 ASCO Genitourinary Cancers Symposium, taking place virtually February 11-13.
Treatment with the immunotherapy nivolumab (Opdivo®) following radical surgery with or without cisplatin-based chemotherapy significantly improved disease-free survival in patients with muscle-invasive urothelial carcinoma, according to a study that will be presented at the 2021 ASCO Genitourinary Cancers Symposium, taking place virtually February 11-13.
Molecular profiling allows clinicians to identify the molecular and genetic signatures that help to deliver treatments that are highly specific to a tumor. This tool has made possible a number of advances in the past year that are improving care for patients with gastrointestinal (GI) cancers. In recognition of this progress, the American Society of Clinical Oncology (ASCO) has named Molecular Profiling Driving Progress in Gastrointestinal Cancers as the Advance of the Year in Clinical Cancer Advances 2021 — just released today.
ALEXANDRIA, Va. – Eight oncology practices in eight different U.S. metropolitan areas with high rates of breast cancer disparities between Black and white Americans have been selected to participate in the American Society of Clinical Oncology’s (ASCO) quality programs, including the Quality Oncology Practice Initiative (QOPI®) and Quality Training Program (QTP). Today ASCO and Susan G. Komen (Komen), with funding from the Fund II Foundation for each practice’s training and participation, announced the recipients. The three-year program, will be administered through Conquer Cancer, the ASCO Foundation.